Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary P26

14 Liver Transplant for Hepatocellular Carcinoma 235 51. Aloia TA, Fahy BN (2008) A decision analysis model predicts the optimal treatment path-way for patients with colorectal cancer and resectable synchronous liver metastases. Clin Colorectal Cancer 7:197–201 52. Lu DS, Yu NC, Raman SS et al (2005) Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41:1130–1137 53. Lu DS, Yu NC, Raman SS et al (2005) Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 234:954–960 54. Mazzaferro V, Battiston C, Perrone S et al (2004) Radiofrequency ablation of small hepatocel-lular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 240:900–909 55. Salem R, Thurston KG (2006) Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 17:1571–1593 56. Kulik LM, Atassi B, van Holsbeeck L et al (2006) Yttrium-90 microspheres (TheraSphere) treatmentofunresectablehepatocellularcarcinoma:downstagingtoresection,RFAandbridge to transplantation. J Surg Oncol 94:572–586 57. Riaz A, Kulik L, Lewandowski RJ et al (2009) Radiologic-pathologic correlation of hepato-cellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49:1185–1193 58. LoCM,LiuCL,ChanSCetal(2007) Arandomized,controlledtrialofpostoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245:831–842 59. Simonetti RG, Liberati A, Angiolini C, Pagliaro L (1997) Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 8:117–136 60. Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300 61. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390 62. Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312–1327 63. Fernandez JA, Robles R, Marin C et al (2003) Can we expand the indications for liver trans-plantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc 35:1818–1820 64. Leung JY, Zhu AX, Gordon FD et al (2004) Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl 10:1343–1354 65. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP (2002) Liver transplanta-tion for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 8:765–774 66. Mazzaferro V, Llovet JM, Miceli R et al (2009) Predicting survival after liver transplan-tation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10:35–43 67. Majno PE, Adam R, Bismuth H et al (1997) Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 226:688–701 68. Yao FY, Hirose R, LaBerge JM et al (2005) A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 11:1505–1514 69. Llovet JM, Schwartz M, Fuster J, Bruix J (2006) Expanded criteria for hepatocellular car-cinoma through down-staging prior to liver transplantation: not yet there. Semin Liver Dis 26:248–253 70. Belghiti J, Cortes A, Abdalla EK et al (2003) Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 238:885–893 71. Fong Y, Sun RL, Jarnagin W, Blumgart LH (1999) An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 229:790–800 236 T.A. Aloia et al. 72. Ercolani G, Grazi GL, Ravaioli M et al (2003) Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 237:536–543 73. Adam R, Azoulay D, Castaing D et al (2003) Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 238:508–519 74. Kulik L, Abecassis M (2004) Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S277–S282 75. Fisher RA, Kulik LM, Freise CE et al (2007) Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 7: 1601–1608 76. Thuluvath PJ, Yoo HY (2004) Graft and patient survival after adult live donor liver transplan-tation compared to a matched cohort who received a deceased donor transplantation. Liver Transpl 10:1263–1238 77. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG (2005) Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 11:1265–1272 78. Lo CM, Fan ST, Liu CL, Chan SC, Wong J (2004) The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 10:440–447 79. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A (2001) Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 33:1073–1079 80. Zavaglia C, De Carlis L, Alberti AB et al (2005) Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 100:2708–2716 81. Margarit C, Charco R, Hidalgo E, Allende H, Castells L, Bilbao I (2002) Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg 26:257–263 82. Schlitt HJ, Neipp M, Weimann A et al (1999) Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 17:324–331 83. Shimoda M, Ghobrial RM, Carmody IC et al (2004) Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl 10:1478–1486 84. Thuluvath PJ, Maheshwari A, Thuluvath NP, Nguyen GC, Segev DL (2009) Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus. Liver Transpl 15:754–762 85. Klintmalm GB (1998) Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 228:479–490 86. Pawlik TM, Delman KA, Vauthey JN et al (2005) Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 11:1086–1092 87. Esnaola NF, Lauwers GY, Mirza NQ et al (2002) Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 6:224–232 88. Busuttil RW, Farmer DG, Yersiz H et al (2005) Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg 241:905–918 89. Vivarelli M, Bellusci R, Cucchetti A et al (2002) Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 74:1746–1751 90. Vivarelli M, Cucchetti A, Piscaglia F et al (2005) Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 11:497–503 91. Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135 14 Liver Transplant for Hepatocellular Carcinoma 237 92. AloiaTA,GossJA(2009) Areportofoutcomesafterorthotopic livertransplantwithallografts from heparin antibody-positive donors. Exp Clin Transplant 7:13–17 93. Guba M, Steinbauer M, Ruhland V et al (2002) Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma. Oncol Reports 9:981–984 94. Schumacher G, Oidtmann M, Rosewicz S et al (2002) Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 34:1392–1393 95. Kneteman NM, Oberholzer J, Al Saghier M et al (2004) Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 10:1301–1311 96. Marsh JW, Finkelstein SD, Demetris AJ et al (2003) Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl 9:664–671 97. UNOS/OPTN policy 3.6.4.4. http://www.optn.org. Accessed November 2009 Chapter 15 Vascular Resection for Hepatocellular Carcinoma Robin D. Kim and Alan W. Hemming Keywords Vascular resection · Vascular reconstruction · HCC · Intraoperative strategies for hepatic/vascular resections · Ante situm procedure Introduction Liver surgery has progressed over the last two decades to become a distinct area of specialization. Strategies such as portal vein embolization (Chapter 11) to induce growth of the planned liver remnant permit more aggressive resections, and improved imaging allows the surgeon to assess tumor position in relation to the intrahepatic vasculature. Liver transplantation has also progressed, but has been limited by the shortage of cadaveric donors. The development of live donor liver transplantation in response to this organ shortage has, in turn, led to techniques that can also be applied in non-transplant liver surgery. Resection and reconstruction of portal vein, hepatic artery, bile duct, and hepatic veins, all standard components of live donor liver transplantation, can be used in resecting complex HCC lesions by surgeons experienced in techniques developed for both liver resection and trans-plantation. Vascular resection and reconstruction is utilized to both achieve adequate oncologic tumor clearance and also preserve uninvolved hepatic parenchyma when vascular inflow or outflow is involved. In this chapter, we examine the role and techniques of vascular resection and reconstruction for HCC. A.W. Hemming ( ) Division of Transplantation and Hepatobiliary Surgery, Department of Surgery, University of California, San Diego, CA, USA K.M. McMasters, J.-N. Vauthey (eds.), Hepatocellular Carcinoma, 239 DOI 10.1007/978-1-60327-522-4_15, C Springer Science+Business Media, LLC 2011 ... - tailieumienphi.vn